Australia markets closed
  • ALL ORDS

    7,320.70
    +8.70 (+0.12%)
     
  • ASX 200

    7,060.70
    +5.30 (+0.08%)
     
  • AUD/USD

    0.7735
    +0.0028 (+0.37%)
     
  • OIL

    62.17
    +0.74 (+1.20%)
     
  • GOLD

    1,775.20
    -6.80 (-0.38%)
     
  • BTC-AUD

    63,489.78
    -7,568.67 (-10.65%)
     
  • CMC Crypto 200

    1,125.41
    +1.51 (+0.13%)
     
  • AUD/EUR

    0.6414
    +0.0006 (+0.09%)
     
  • AUD/NZD

    1.0779
    +0.0024 (+0.22%)
     
  • NZX 50

    12,650.64
    +73.16 (+0.58%)
     
  • NASDAQ

    13,899.31
    +136.96 (+1.00%)
     
  • FTSE

    6,929.24
    -9.00 (-0.13%)
     
  • Dow Jones

    34,012.30
    +196.40 (+0.58%)
     
  • DAX

    15,252.19
    -68.33 (-0.45%)
     
  • Hang Seng

    29,078.75
    +323.41 (+1.12%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     

Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%?

Keith Speights, The Motley Fool
·4-min read
Could Coronavirus Variants Boost Pfizer's Vaccine Sales By 50%?

Fifteen billion dollars: That's how much Pfizer (NYSE: PFE) projected last month in its Q4 update that it will make this year from its COVID-19 vaccine, BNT162b2. Since Pfizer's update, the U.S. government has ordered another 100 million doses of BNT162b2. Pfizer and BioNTech announced last week that they've begun a study to evaluate a third dose of BNT162b2.